EPRX
NASDAQ · Biotechnology
Eupraxia Pharmaceuticals Inc
$6.48
+0.19 (+3.02%)
Open$6.45
Previous Close$6.29
Day High$6.53
Day Low$6.28
52W High$12.86
52W Low$5.82
Volume—
Avg Volume46.2K
Market Cap599.05M
P/E Ratio—
EPS$-0.96
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+584.3% upside
Current
$6.48
$6.48
Target
$44.34
$44.34
$25.23
$44.34 avg
$48.95
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 121.08M | 121.80M | 129.11M |
| Net Income | -20,292,332 | -19,070,968 | -17,081,441 |
| Profit Margin | -16.8% | -15.7% | -13.2% |
| EBITDA | -26,386,283 | -29,891,368 | -27,935,877 |
| Free Cash Flow | -23,062,869 | -20,449,670 | -23,278,243 |
| Rev Growth | +21.7% | +19.1% | -8.5% |
| Debt/Equity | 0.16 | 0.18 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |